Grant Number:	5R37CA226081-03 Interpret this number
Primary Investigator:	Han, Summer
Organization:	Stanford University
Project Title:	Evaluation of Genetic, Clinical, and Environmental Risk Factors to Establish Effective Screening Strategies for Second Primary Lung Cancer
Fiscal Year:	2020

Lung cancer (LC) is a leading cause of cancer deaths in the U.S. The widespread adoption of computed tomography (CT) screening enables the early detection of lung cancer and is expected to increase the number of long-term LC survivors. The estimated number of LC survivors is approximately 412,230 as of 2012 and is projected to be over a half million in 2022. Recent studies show that LC survivors have a high risk of developing second primary lung cancer (SPLC), the incidence of which is around 4-6 times higher than that of initial primary lung cancer (IPLC) in the general population. While national lung screening guidelines have been established for IPLC by the U.S. Preventive Services Task Force (USPSTF), no such consensus guidelines exist for LC survivors who are exposed to a high risk of SPLC. Furthermore, the factors that contribute to the development of SPLC have not yet been established. Our long-term goal is to reduce the overall LC mortality in the U.S. population by focusing on SPLC. The overall objectives of this application are to identify the genetic, clinical, and environmental determinants for SPLC, to assess an individual’s risk of developing SPLC, and to evaluate efficient lung screening strategies for SPLC to help inform the development of consensus screening guidelines for LC survivors. Our aims are: (AIM 1) To identify the genetic, environmental, clinical, and demographic risk factors for SPLC and to develop a risk prediction model for SPLC. We will use cohort data from the Transdisciplinary Research in Cancer of the Lung (TRICL) and the International Lung Cancer Consortium (ILCCO) to evaluate risk factors for SPLC; (AIM 2) To evaluate optimal CT screening strategies for SPLC by estimating the population-level harms and benefits of CT screening under various selection criteria. We will develop a stochastic simulation model for SPLC that integrates the incidence, progression, and survival of SPLC to quantify the population-level harms and benefits of screening for SPLC under various risk- based selection criteria; (AIM 3) To estimate the lifetime costs and to assess the cost-effectiveness of CT screening strategies for SPLC in the general U.S. population. The contribution of our research will be significant because it will provide a better understanding of the etiology of SPLC by identifying various risk factors for SPLC using comprehensive population-based data. Second, the completion of our research will provide a valuable decision tool for evaluating an individual’s risk of developing SPLC, which can help identify high-risk individuals for screening. Finally, by evaluating the potential harms and benefits of lung cancer screening for SPLC under various criteria, our research will provide a set of optimal CT screening strategies, the results of which will reduce clinicians’ uncertainty on how to best guide LC survivors for CT screening.




Risk Model-Based Lung Cancer Screening and Racial and Ethnic Disparities in the US.
Authors: Choi E. , Ding V.Y. , Luo S.J. , Ten Haaf K. , Wu J.T. , Aredo J.V. , Wilkens L.R. , Freedman N.D. , Backhus L.M. , Leung A.N. , et al. .
Source: Jama Oncology, 2023-12-01 00:00:00.0; 9(12), p. 1640-1648.
PMID: 37883107
Related Citations

Second Primary Lung Cancer Among Lung Cancer Survivors Who Never Smoked.
Authors: Choi E. , Su C.C. , Wu J.T. , Aredo J.V. , Neal J.W. , Leung A.N. , Backhus L.M. , Lui N.S. , Le Marchand L. , Stram D.O. , et al. .
Source: Jama Network Open, 2023-11-01 00:00:00.0; 6(11), p. e2343278.
EPub date: 2023-11-01 00:00:00.0.
PMID: 37966839
Related Citations

Risk model-based management for second primary lung cancer among lung cancer survivors through a validated risk prediction model.
Authors: Choi E. , Luo S.J. , Ding V.Y. , Wu J.T. , Kumar A.V. , Wampfler J. , Tammemägi M.C. , Wilkens L.R. , Aredo J.V. , Backhus L.M. , et al. .
Source: Cancer, 2023-10-25 00:00:00.0; , .
EPub date: 2023-10-25 00:00:00.0.
PMID: 37877788
Related Citations

Optimizing Lung Cancer Screening With Risk Prediction: Current Challenges and the Emerging Role of Biomarkers.
Authors: Wu J.T. , Wakelee H.A. , Han S.S. .
Source: Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology, 2023-09-20 00:00:00.0; 41(27), p. 4341-4347.
EPub date: 2023-08-04 00:00:00.0.
PMID: 37540816
Related Citations

Software Application Profile: dynamicLM-a tool for performing dynamic risk prediction using a landmark supermodel for survival data under competing risks.
Authors: Fries A.H. , Choi E. , Wu J.T. , Lee J.H. , Ding V.Y. , Huang R.J. , Liang S.Y. , Wakelee H.A. , Wilkens L.R. , Cheng I. , et al. .
Source: International Journal Of Epidemiology, 2023-09-06 00:00:00.0; , .
EPub date: 2023-09-06 00:00:00.0.
PMID: 37670428
Related Citations

Overall Survival Among Patients With De Novo Stage IV Metastatic and Distant Metastatic Recurrent Non-Small Cell Lung Cancer.
Authors: Su C.C. , Wu J.T. , Choi E. , Myall N.J. , Neal J.W. , Kurian A.W. , Stehr H. , Wood D. , Henry S.M. , Backhus L.M. , et al. .
Source: Jama Network Open, 2023-09-05 00:00:00.0; 6(9), p. e2335813.
EPub date: 2023-09-05 00:00:00.0.
PMID: 37751203
Related Citations

Racial and Ethnic Disparities in Lung Cancer Screening by the 2021 USPSTF Guidelines Versus Risk-Based Criteria: The Multiethnic Cohort Study.
Authors: Aredo J.V. , Choi E. , Ding V.Y. , Tammemägi M.C. , Ten Haaf K. , Luo S.J. , Freedman N.D. , Wilkens L.R. , Le Marchand L. , Wakelee H.A. , et al. .
Source: Jnci Cancer Spectrum, 2022-05-02 00:00:00.0; 6(3), .
PMID: 35642317
Related Citations

The Survival Impact of Second Primary Lung Cancer in Patients with Lung Cancer.
Authors: Choi E. , Luo S.J. , Aredo J.V. , Backhus L.M. , Wilkens L.R. , Su C.C. , Neal J.W. , Le Marchand L. , Cheng I. , Wakelee H.A. , et al. .
Source: Journal Of The National Cancer Institute, 2021-12-10 00:00:00.0; , .
EPub date: 2021-12-10 00:00:00.0.
PMID: 34893871
Related Citations

Cost-effectiveness Evaluation of the 2021 US Preventive Services Task Force Recommendation for Lung Cancer Screening.
Authors: Toumazis I. , de Nijs K. , Cao P. , Bastani M. , Munshi V. , Ten Haaf K. , Jeon J. , Gazelle G.S. , Feuer E.J. , de Koning H.J. , et al. .
Source: Jama Oncology, 2021-10-21 00:00:00.0; , .
EPub date: 2021-10-21 00:00:00.0.
PMID: 34673885
Related Citations

Smoking Cessation After Lung Cancer Diagnosis and the Risk of Second Primary Lung Cancer: The Multiethnic Cohort Study.
Authors: Luo S.J. , Choi E. , Aredo J.V. , Wilkens L.R. , Tammemägi M.C. , Le Marchand L. , Cheng I. , Wakelee H.A. , Han S.S. .
Source: Jnci Cancer Spectrum, 2021 Oct; 5(5), p. pkab076.
EPub date: 2021-08-23 00:00:00.0.
PMID: 34611582
Related Citations

A Robust Test for Additive Gene-Environment Interaction Under the Trend Effect of Genotype Using an Empirical Bayes-Type Shrinkage Estimator.
Authors: Sanyal N. , Napolioni V. , de Rochemonteix M. , Belloy M.E. , Caporaso N.E. , Landi M.T. , Greicius M.D. , Chatterjee N. , Han S.S. .
Source: American Journal Of Epidemiology, 2021-09-01 00:00:00.0; 190(9), p. 1948-1960.
PMID: 33942053
Related Citations

A Moving Target: Integration of Smoking Cessation Into Screening for Second Primary Lung Cancer.
Authors: Aredo J.V. , Wakelee H.A. , Han S.S. .
Source: Journal Of Thoracic Oncology : Official Publication Of The International Association For The Study Of Lung Cancer, 2021 08; 16(8), p. e59-e60.
PMID: 34304856
Related Citations

Development and Validation of a Risk Prediction Tool for Second Primary Lung Cancer.
Authors: Choi E. , Sanyal N. , Ding V.Y. , Gardner R.M. , Aredo J.V. , Lee J. , Wu J.T. , Hickey T.P. , Barrett B. , Riley T.L. , et al. .
Source: Journal Of The National Cancer Institute, 2021-07-13 00:00:00.0; , .
EPub date: 2021-07-13 00:00:00.0.
PMID: 34255071
Related Citations

Tobacco Smoking and Risk of Second Primary Lung Cancer.
Authors: Aredo J.V. , Luo S.J. , Gardner R.M. , Sanyal N. , Choi E. , Hickey T.P. , Riley T.L. , Huang W.Y. , Kurian A.W. , Leung A.N. , et al. .
Source: Journal Of Thoracic Oncology : Official Publication Of The International Association For The Study Of Lung Cancer, 2021 Jun; 16(6), p. 968-979.
EPub date: 2021-03-17 00:00:00.0.
PMID: 33722709
Related Citations

Metabolomic profiling for second primary lung cancer: A pilot case-control study.
Authors: Aredo J.V. , Purington N. , Su L. , Luo S.J. , Diao N. , Christiani D.C. , Wakelee H.A. , Han S.S. .
Source: Lung Cancer (amsterdam, Netherlands), 2021 May; 155, p. 61-67.
EPub date: 2021-03-11 00:00:00.0.
PMID: 33743383
Related Citations

A Likelihood Ratio Test for Gene-Environment Interaction Based on the Trend Effect of Genotype Under an Additive Risk Model Using the Gene-Environment Independence Assumption.
Authors: de Rochemonteix M. , Napolioni V. , Sanyal N. , Belloy M.E. , Caporaso N.E. , Landi M.T. , Greicius M.D. , Chatterjee N. , Han S.S. .
Source: American Journal Of Epidemiology, 2021-01-04 00:00:00.0; 190(1), p. 129-141.
PMID: 32870973
Related Citations

Disparities of national lung cancer screening guidelines in the U.S. population.
Authors: Han S.S. , Chow E. , Ten Haaf K. , Toumazis I. , Cao P. , Bastani M. , Tammemagi M. , Jeon J. , Feuer E. , Meza R. , et al. .
Source: Journal Of The National Cancer Institute, 2020-02-10 00:00:00.0; , .
EPub date: 2020-02-10 00:00:00.0.
PMID: 32040195
Related Citations

A comparative modeling analysis of risk-based lung cancer screening strategies.
Authors: Ten Haaf K. , Bastani M. , Cao P. , Jeon J. , Toumazis I. , Han S.S. , Plevritis S.K. , Blom E.F. , Kong C.Y. , Tammemägi M.C. , et al. .
Source: Journal Of The National Cancer Institute, 2019-09-30 00:00:00.0; , .
EPub date: 2019-09-30 00:00:00.0.
PMID: 31566216
Related Citations

Caution Needed for Analyzing the Risks of Second Cancers.
Authors: Han S.S. , Plevritis S.K. , Wakelee H.A. .
Source: Journal Of Thoracic Oncology : Official Publication Of The International Association For The Study Of Lung Cancer, 2018 09; 13(9), p. e172-e173.
PMID: 30166015
Related Citations